Stockscreener 앱 받기
21.99
1.30%
-0.29
시간 외 거래:
21.99
Arcus Biosciences Inc 주식(RCUS)의 최신 뉴스
Arcus Biosciences (NYSE:RCUS) Insider Richard Markus Sells 4,494 Shares - MarketBeat
Insider Selling: Arcus Biosciences (NYSE:RCUS) CAO Sells 2,113 Shares of Stock - MarketBeat
Carolyn Tang Sells 7,658 Shares of Arcus Biosciences (NYSE:RCUS) Stock - MarketBeat
Arcus Biosciences (NYSE:RCUS) President Sells $245,603.00 in Stock - MarketBeat
Richard Markus Sells 5,052 Shares of Arcus Biosciences (NYSE:RCUS) Stock - MarketBeat
Jennifer Jarrett Sells 9,983 Shares of Arcus Biosciences (NYSE:RCUS) Stock - MarketBeat
Arcus Biosciences (NYSE:RCUS) General Counsel Sells $150,909.60 in Stock - MarketBeat
Arcus Biosciences Insider Sold Shares Worth $318,496, According to a Recent SEC Filing - marketscreener.com
Arcus Biosciences amends loan agreement, extends maturity and updates terms - Investing.com
Arcus Biosciences Amends Loan Facility, Extends Maturity Terms - TipRanks
Cancer-focused Arcus Biosciences to present at major health conference - Stock Titan
February 2026 Options Now Available For Arcus Biosciences (RCUS) - Nasdaq
Arcus Biosciences: Casdatifan Takes Center Stage After STAR-221 (NYSE:RCUS) - Seeking Alpha
This Growth Stock With 137% Upside Faces New Challenge: Buy, Hold or Sell? - inkl
RCUS Stock Down on Decision to Discontinue GILD Partnered Study - Finviz
Arcus Biosciences stock price target raised to $32 at H.C. Wainwright - Investing.com Canada
Domvanalimab failure bad news for Arcus and TIGIT class - The Pharma Letter
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Assessing Arcus Biosciences’ Valuation After Halting Key GI Trials and Pivoting to Casdatifan-Focused Strategy - simplywall.st
Arcus Biosciences (RCUS) Stock News, Forecasts and Analyst Targets — Dec. 14, 2025 Update - ts2.tech
Why Arcus Biosciences (RCUS) Is Down 15.4% After Halting Key Domvanalimab Cancer Trials And What's Next - Yahoo Finance
Arcus Biosciences (NYSE:RCUS) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Arcus Biosciences (NYSE:RCUS) Shares Gap DownHere's What Happened - MarketBeat
Arcus Biosciences (NYSE:RCUS) Price Target Raised to $32.00 at HC Wainwright - MarketBeat
Arcus Biosciences Target of Unusually Large Options Trading (NYSE:RCUS) - MarketBeat
Gilead, Arcus scrap late-stage trial of cancer drug combo - WTVB
Why Arcus Biosciences just reversed its 287% eight-month winning streak - MSN
HC Wainwright & Co. Maintains Arcus Biosciences (RCUS) Buy Recommendation - Nasdaq
Arcus Calls Quits On Anti-TIGIT Candidate After Phase III Termination - Citeline News & Insights
Arcus shifts effort, bears down on would-be ‘anchor’ in RCC - BioWorld MedTech
Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney DrugArcus Biosciences (NYSE:RCUS) - Benzinga
H.C. Wainwright raises Arcus Biosciences stock price target to $32 on lower expenses - Investing.com Canada
Truist Securities lowers Arcus Biosciences stock price target on trial failure - Investing.com Canada
Why Did Arcus Biosciences Stock Slump 10% Today? - Asianet Newsable
RCUS: HC Wainwright & Co. Raises Price Target for Arcus Bioscien - GuruFocus
Arcus cancels work on Gilead-partnered cancer combo after trial setback - BioPharma Dive
Truist Securities Adjusts Arcus Biosciences Price Target to $30 From $39, Maintains Buy Rating - marketscreener.com
Arcus Biosciences (RCUS) Shares Decline Over 11% in Recent Tradi - GuruFocus
Arcus scraps late-stage cancer trial after weak survival data - Reuters
Arcus Biosciences (RCUS) Drops After Halting Phase 3 Cancer Tria - GuruFocus
Arcus Biosciences Stock (RCUS) Collapses 17% after Failed Stomach Cancer Study - TipRanks
GILD: Gilead and Arcus End STAR-221 Study Due to Lack of Efficac - GuruFocus
Arcus, Gilead to Discontinue Phase 3 Trial of Potential Cancer Treatment -- Update - marketscreener.com
Arcus Biosciences Discontinuing Gastric, Esophogeal Cancer Candidate Trial; Shares Fall - marketscreener.com
Gilead and Arcus halt late-stage study for anti-TIGIT cancer drug - Seeking Alpha
Arcus Biosciences to Discontinue Phase 3 Trial of Potential Cancer Treatment - marketscreener.com
Arcus Biosciences stock falls after discontinuing phase 3 cancer study By Investing.com - Investing.com Australia
Arcus Biosciences Discontinues Phase 3 STAR-221 Study - TradingView — Track All Markets
Arcus Provides Update On Phase 3 STAR-221 Study And Concentrates Its Research And Development Investment On Casdatifan And Emerging Inflammation And Immunology Portfolio - TradingView — Track All Markets
Arcus Biosciences stock falls after discontinuing phase 3 cancer study - Investing.com
Arcus Biosciences (NYSE: RCUS) ends STAR-221, backs casdatifan and I&I pipeline into 2028 - Stock Titan
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $431,000 Holdings in Arcus Biosciences, Inc. $RCUS - MarketBeat
Decliners Report: Why Arcus Biosciences Inc stock attracts global investors2025 Volatility Report & Weekly Watchlist for Consistent Profits - moha.gov.vn
Avoiding Lag: Real-Time Signals in (RCUS) Movement - news.stocktradersdaily.com
Arcus Biosciences Announces New Employment Inducement Grants - marketscreener.com
Arcus Biosciences (NYSE: RCUS) sets $25.80 inducement grant under 2020 plan - Stock Titan
Arcus Biosciences (NYSE:RCUS) Reaches New 1-Year HighWhat's Next? - MarketBeat
Is Arcus Biosciences Stock Built to Withstand a Pullback? - Trefis
Fisher Asset Management LLC Decreases Stock Holdings in Arcus Biosciences, Inc. $RCUS - MarketBeat
Insider Selling: Arcus Biosciences (NYSE:RCUS) President Sells 82,997 Shares of Stock - MarketBeat
Arcus Biosciences, Inc. $RCUS Shares Acquired by Tema Etfs LLC - MarketBeat
Arcus Biosciences (NYSE:RCUS) Downgraded by Wall Street Zen to Sell - MarketBeat
Is Arcus Biosciences Inc. stock cheap by valuation metricsWeekly Market Outlook & Low Risk High Win Rate Stock Picks - Newser
0.31%
0.33%
자본화:
|
볼륨(24시간):